EIC Accelerator Winner Ganymed Robotics in the Knee Robot Race

29 September 20261,271 words7 min

Knee replacement is, as Ganymed's 2021 EIC announcement put it, a common and fast-growing operation, and the company then estimated that most procedures lacked technological assistance. Many existing surgical robots track the anatomy with optical markers fixed to pins in the patient's bones. Ganymed Robotics, founded in Paris in 2018, is building a robotic assistant that tracks the knee with cameras and computer vision instead, with no markers at all.

The European Innovation Council granted €2,485,995.75 towards a two-year, €3.55 million project to finish the robot. Its announced €36 million financing includes public investment and a loan. The company website reviewed on 2 November 2026 says the product remains under development, unapproved by the FDA or any other regulator, and unavailable for sale. Separately, the co-founder who led the company left in 2025.

€2.49MEIC grant, 70% of a €3.55M project
€36MSeries B raised in 2022 and 2023
12Cadaver labs completed by the end of 2023
PreclinicalCurrent product status stated on the company website

Company file

Legal entity
Ganymed Robotics SAS, SIREN 840 634 356
Founded
2018, Paris
Leadership
Michel Thérin (executive chairman, 2025); Frédéric Banegas (interim CEO and COO)
Product
Co-manipulated robotic assistant for total knee replacement
Board investors
Cathay Capital, Crédit Mutuel Innovation, Kurma Partners
EIC project
Ganymed, 1 Jan 2022 to 31 Dec 2023, closed
EIC Fund
Listed in the EIC Fund portfolio
R&D and support
41 FTEs reported during the final project period

Where Ganymed Stands Today

Ganymed remains a development-stage medtech according to its current product disclaimer. Its August 2025 announcement describes preclinical system tests and confirms Sophie Cahen's departure, Michel Thérin's appointment as executive chairman and Frédéric Banegas as COO and interim CEO. The current leadership page retains those roles. A leadership transition alone does not establish a technical or financial setback.

The July 2022 financing announcement records a €21 million first close. The January 2023 extension brought the announced total to €36 million. Its release splits the extension into €14 million from EIC Fund and Cap Horn and a €1 million Bpifrance loan. An EIC publication records a €10 million investment commitment; that is not a separate addition to the €36 million total or evidence of its precise payment dates.

The Technology: Seeing the Knee Without Markers

An orthopaedic robot needs to know exactly where the bones are. Marker-based systems achieve this with arrays fixed to pins in the femur and tibia, which Ganymed's marker-less approach is designed to avoid. Ganymed's approach, set out in its CORDIS objective, is "contactless anatomical localization" with computer vision: cameras and algorithms recognise and track the bone surfaces directly. The robot is co-manipulated, meaning the surgeon guides it while it constrains the cuts to the plan.

The company's pitch is also economic: a "compact, ergonomic, intuitive, and cost-effective" device aimed at procedures without technological assistance, which the original objective put at 95%, in part because current robots are large and expensive.

What the EIC Project Promised, and What CORDIS Shows

The EIC project

EU contribution: 70% of a €3.55M project

The Ganymed project ran from January 2022 to December 2023.

CORDIS project 190121972. Values in € millions.

The project ran from 1 January 2022 to 31 December 2023. Its report is detailed. The hardware design was finalised and the robot entered verification and validation. Software development and industrialisation followed the proof of concept. The report describes a 91-patient clinical study validating the vision algorithms on real anatomy, and twelve cadaver labs had been run by the end of 2023, including full prosthesis implantation with commercial implants. The report says R&D and support teams grew from 23 to 41 full-time equivalents; these are not R&D-only or current company totals.

The 2022 investor release describes a 100-patient observational study, whereas CORDIS reports 91 patients. The reviewed sources do not reconcile those counts. The participating hospital lists VALALGON as an algorithm-validation study during knee replacement. This supports patient-data collection, not a claim that the robot performed the surgery.

The team

Reported R&D and support headcount rose from 23 to 41

FTEs for R&D and support teams in the final-period beneficiary summary. Not R&D-only or current company staffing; exact measurement dates are not given.

CORDIS project 190121972, periodic report.

  1. A finished robot designDeliveredHardware finalised and in verification and validation by the end of 2023.
  2. Marker-less navigation provenPartialBeneficiary-reported patient and cadaver testing. This does not establish improved patient outcomes; a peer-reviewed robot-assisted clinical outcome study was not identified in title/company searches on 2 November 2026.
  3. Regulatory clearanceUnapprovedThe company website reviewed on 2 November 2026 explicitly says the product is not cleared or approved. No approval deadline was established from the public project summary.
  4. Use in surgeryNone publishedNo robot-assisted patient operation was identified in the company homepage, news pages or CORDIS summary reviewed on 2 November 2026; patient imaging studies are a different use.

What Has Happened Since the Award

The record

Development and financing milestones; product remains unapproved

Company homepage reviewed 2 November 2026 describes an unapproved preclinical product. Patient imaging studies do not establish robot-assisted surgery.

  1. 2018Company foundedGanymed Robotics SAS, Paris, SIREN 840 634 356
  2. Jun 2021EIC Accelerator cut-offRobotic assistant for knee replacement submitted under the Open call
  3. Jan 2022EIC project startsTwo-year project to finish the robot and validate its vision system€2.49M grant
  4. 2022Series B first closeInvestors on the board include Cathay Capital, Crédit Mutuel Innovation and Kurma€21M
  5. 2023Series B extensionAnnounced total €36M; extension includes EIC Fund/Cap Horn investment and a €1M Bpifrance loan€15M
  6. Dec 2023EIC project closes91-patient observational study, 12 cadaver labs, robot in verification and validation
  7. 2025Leadership changeCo-founder Sophie Cahen leaves; Michel Thérin chairman, Frédéric Banegas interim CEO
  8. Nov 2026 reviewCompany product disclaimerUnder development, not cleared or approved, and unavailable for commercial sale

CORDIS beneficiary report, Pappers filing summary and Ganymed company/investor announcements.

The Money

The filed-account summary on Pappers reports net losses of €1.03 million in 2022, €5.53 million in 2023 and €5.03 million in 2024. Equity was €12.2 million, €29.9 million and €27.6 million respectively; reported cash was €22.7 million at the end of 2024. These historical figures do not establish current liquidity or the cost of reaching approval. Losses are not the same as cash expenditure.

The cost

Reported net losses exceeded €5M in 2023 and 2024

Net losses, not cash expenditure, in millions of euros. Rounded filing-summary figures.

Filed accounts via Pappers.

The capital

Equity was €27.6M at the end of 2024

Year-end accounting equity, not cash or runway, in millions of euros. Financing announcements do not reconcile every equity movement.

Filed accounts via Pappers.

Historical capital, unknown current runway

Equity is not a cash balance, and dividing it by annual net loss does not establish runway. Even the reported 2024 cash position is dated: current spending, commitments and financing are needed to assess how long resources will last. The reviewed sources do not supply a verified approval timetable.

Why Europe Should Care

A European surgical robotics company with a distinct technical approach, funded by French investors, the EIC grant and the EIC Fund, keeps development of this technology in Europe. The CORDIS objective also points to an ageing population driving demand for joint replacement, a pressure felt across European health systems.

What the project promised

A compact, cost-effective, marker-less robot for joint replacement; these are development objectives, with the 95% unassisted-procedure estimate stated at the time of the original proposal.

What the record shows

Reported design and testing milestones, patient imaging data and €36M financing including public funds and a loan. The product remains unapproved according to the company; commercial scale is unverified.

The Verdict

Development milestones, commercial approval still ahead

The beneficiary reports progress into verification and validation, supported by cadaver testing and patient imaging. The financing includes public and private investment and a loan, so the full €36 million cannot be described as private capital. The company's current product disclaimer confirms that approval and commercial availability remain ahead. The public summary does not establish that an approval deadline was missed, and observational imaging data should not be confused with robot-assisted patient surgery.

Ganymed Robotics has not been asked for comment for this article. It is based entirely on public records, company statements and EU project data, linked throughout.

Industry

HealthMedical devices

Focus
  • Orthopaedic and spine devices
Technologies
  • Robotics
  • Computer vision
Keywords
  • Surgical robotics
  • Knee replacement
  • Orthopaedic surgery
  • Marker-free navigation